Arca biopharma announces first quarter 2024 financial results and provides corporate update

Arca biopharma and oruka therapeutics announce merger agreement arca biopharma appoints thomas keuer as president westminster, colo., april 25, 2024 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), (the “company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.
ABIO Ratings Summary
ABIO Quant Ranking